AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Group 10 secretory phospholipase A2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

O15496

UPID:

PA2GX_HUMAN

Alternative names:

Group X secretory phospholipase A2; Phosphatidylcholine 2-acylhydrolase 10

Alternative UPACC:

O15496; Q14DU3; Q6NT23

Background:

Group 10 secretory phospholipase A2 (sPLA2), also known as Phosphatidylcholine 2-acylhydrolase 10, plays a pivotal role in lipid metabolism by hydrolyzing the sn-2 bond of phospholipids, favoring phosphatidylcholines and phosphatidylglycerols. It is involved in the remodeling of lipoproteins such as VLDL, LDL, and HDL, and regulates macrophage differentiation, contributing to the inflammatory response and tissue regeneration.

Therapeutic significance:

Understanding the role of Group 10 secretory phospholipase A2 could open doors to potential therapeutic strategies, particularly in managing lipid-related disorders, inflammation, and promoting tissue regeneration.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.